Home › Companies › Silence Therapeutics plc

Silence Therapeutics plc (SLN) proxy voting records

How asset managers voted at Silence Therapeutics plc’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

• TickerSLN
• CUSIP issuer number82686Q
• SEC CIK1479615

Recent shareholder votes

• June 16, 2026 annual meeting (2025-2026 proxy season): 8 items in Silence Therapeutics plc's official results (Form 8-K, filed June 16, 2026); lowest support 99% of votes cast (To re-appoint as a director of the Company James Ede-Golightly.). Full results and how funds voted.
• June 26, 2025 annual meeting (2024-2025 proxy season): 11 items in Silence Therapeutics plc's official results (Form 8-K, filed June 27, 2025); lowest support 96% of votes cast (To approve, on an advisory basis, the compensation of the…). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Earlier seasons list this company under the name SILENCE THERAPEUTICS PLC, as its holders filed it.

Explore Silence Therapeutics plc in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.